Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Classic Hodgkin Lymphoma Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Pentamidine
Drug
Lead sponsor
Reinhold Munker
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced May 21, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
Interventions
Pembrolizumab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced May 21, 2026, 6:33 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Interventions
Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced May 21, 2026, 6:33 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
Interventions
MGD024
Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 21, 2026, 6:33 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Tenalisib, Pembrolizumab
Drug · Biological
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Detroit, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
16
States / cities
Los Angeles, California • Greenwood Village, Colorado • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Genetically Engineered Lymphocyte Therapy
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Bortezomib, Carboplatin, Etoposide, Ifosfamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced May 21, 2026, 6:33 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
Interventions
Nivolumab, Autologous CD30.CAR-T, Fludarabine, Bendamustine
Drug
Lead sponsor
Tessa Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Classical Hodgkin Lymphoma
Interventions
Sabestomig (AZD7789)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 101 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
6
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Etoposide, Ifosfamide, Lenalidomide, Positron Emission Tomography, Tafasitamab
Procedure · Drug · Biological
Lead sponsor
David Bond, MD
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 21, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Relapsed Classic Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Nivolumab
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced May 21, 2026, 6:33 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Magrolimab, Pembrolizumab, PET/CT
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
favezelimab/pembrolizumab, bendamustine, gemcitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 6:33 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced May 21, 2026, 6:33 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Nivolumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Duarte, California • Rochester, Minnesota • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Tislelizumab
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Detroit, Michigan • Knoxville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Lenalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
St Louis, Missouri • Hackensack, New Jersey • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Camidanlumab Tesirine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
16 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Panobinostat, Ifosfamide, Mesna, Carboplatin, Etoposide, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced May 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced May 21, 2026, 6:33 PM EDT